Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy

被引:39
|
作者
Obaro, SK
Deubzer, HE
Newman, VO
Adegbola, RA
Greenwood, BM
Henderson, DC
机构
[1] MRC Labs, Banjul, Gambia
[2] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Immunol, London, England
[3] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England
关键词
pneumococcal polysaccharide vaccine; pregnancy; breast milk; infant;
D O I
10.1097/01.inf.0000143651.54880.09
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In breast-feeding populations, immunization during pregnancy with pneumococcal polysaccharide offers a potentially useful approach to preventing pneumococcal disease in young infants. Methods: Breast milk samples were collected at 0, 2, 4 and 6 months after delivery from Gambian women vaccinated during pregnancy (24-32 weeks gestation) with Pneumovax II (n = 56) or Mengivax A&C (n = 57). Specimens were examined for secretory immunoglobulin A (s-IgA) concentration, subclass distribution and avidity specific to pneumococcal serotypes 4, 6B, 14, 19F and 23F and the antigen mixture in Pneumovax 11 by enzyme-linked immunosorbent assay. Colostral s-IgA and IgG concentrations in paired maternal sera were compared. Results: Colostral s-IgA concentrations specific to all pneumococcal polysaccharide antigens investigated were significantly higher (P < 0.05) among Pneumovax II vaccinees. Titers specific to serotypes 4, 6B and 14 and the vaccine formula remained significantly higher during 6 months, and those for 19F were higher during 4 months. Significantly higher concentrations of vaccine antigen-specific s-IgA antibody were sustained for 6 months after delivery (P = 0.011). Comparison of colostral s-IgA and IgG in serum revealed a significant correlation only among Mengivax A&C vaccinees for pneumococcal polysaccharide 23F (r(s) = 0.68; P less than or equal to 0.0001). Vaccination elicited trends toward increased s-IgA2, reaching significance for serotype 14 and the vaccine formula. Immunization elicited significantly higher s-IgA avidities specific to all pneumococcal polysaccharide antigens studied during 6 months. Conclusions: The public health value of immunization during pregnancy with pneumococcal polysaccharide vaccine in breastfeeding populations warrants further evaluation, particularly in populations with a high incidence of pneumococcal disease in early infancy.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 50 条
  • [31] UNDERUTILIZATION OF PNEUMOCOCCAL VACCINE IN NURSING-HOMES IN WASHINGTON-STATE - REPORT OF A SEROTYPE-SPECIFIC OUTBREAK AND A SURVEY
    QUICK, RE
    HOGE, CW
    HAMILTON, DJ
    WHITNEY, CJ
    BORGES, M
    KOBAYASHI, JM
    AMERICAN JOURNAL OF MEDICINE, 1993, 94 (02): : 149 - 152
  • [32] Pneumococcal Nasopharyngeal Carriage Among Infants Born to Human Immunodeficiency Virus-infected Mothers Immunized With Pneumococcal Polysaccharide Vaccine During Gestation
    Almeida, Volia de Carvalho
    Negrini, Bento V. M.
    Cervi, Maria C.
    Isaac, Marcia de L.
    Mussi-Pinhata, Marisa M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (06) : 466 - 470
  • [33] The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages
    Fabrizio, Kevin
    Manix, Catherine
    Tian, Haijun
    van Rooijen, Nico
    Pirofski, Liise-anne
    VACCINE, 2010, 28 (47) : 7542 - 7550
  • [34] Evaluation of the Specificity of Pneumococcal Polysaccharide Enzyme-Linked Immunosorbent Assay and the Effect of Serum Adsorption Based on Standard Pneumococcal Serogroup- or Serotype-Specific Rabbit Antisera
    Slotved, Hans-Christian
    Guttmann, Christina
    Pedersen, Charlotte Demuth
    Jacobsen, Jasper Neergaard
    Krogfelt, Karen Angeliki
    CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (09) : 1279 - 1284
  • [35] A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies
    Ozdilek, Ahmet
    Huang, Jiachen
    Babb, Rachelle
    Paschall, Amy, V
    Middleton, Dustin R.
    Duke, Jeremy A.
    Pirofski, Liise-Anne
    Mousa, Jarrod J.
    Avci, Fikri Y.
    MBIO, 2021, 12 (03):
  • [36] Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus
    Dagan, R
    Givon-Lavi, N
    Fraser, D
    Lipsitch, M
    Siber, GR
    Kohberger, R
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03): : 367 - 376
  • [37] Age-stratified prevalences of pneurnococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine
    Balmer, Paul
    Borrow, Ray
    Findlow, Jamie
    Warrington, Rosalind
    Frankland, Sarah
    Waight, Pauline
    George, Robert
    Andrews, Nick
    Miller, Elizabeth
    CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (11) : 1442 - 1450
  • [38] Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
    Andrews, Nick J.
    Waight, Pauline A.
    Burbidge, Polly
    Pearce, Emma
    Roalfe, Lucy
    Zancolli, Marta
    Slack, Mary
    Ladhani, Shamez N.
    Miller, Elizabeth
    Goldblatt, David
    LANCET INFECTIOUS DISEASES, 2014, 14 (09): : 839 - 846
  • [39] TYPE-SPECIFIC ANTIBODY-RESPONSES OF VOLUNTEERS IMMUNIZED WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
    MUFSON, MA
    HUGHEY, D
    LYDICK, E
    JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04): : 749 - 750
  • [40] Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia
    Saaka, M.
    Okoko, B. J.
    Kohberger, R. C.
    Jaffar, S.
    Enwere, G.
    Biney, E. E.
    Oluwalana, C.
    Vaughan, A.
    Zaman, S. M. A.
    Asthon, L.
    Goldblatt, D.
    Greenwood, B. M.
    Cutts, F. T.
    Adegbola, R. A.
    VACCINE, 2008, 26 (29-30) : 3719 - 3726